A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety, of STAT-201 in Pediatric Patients Aged 12 to 17 Years (Inclusive) with Active Crohn's Disease
Latest Information Update: 22 Jun 2023
At a glance
- Drugs Naltrexone (Primary)
- Indications Crohn's disease
- Focus Registrational; Therapeutic Use
- Sponsors Biostax
- 01 Mar 2023 According to a Biostax media release, Immune Therapeutics has changed its name to Biostax.
- 15 Feb 2022 According to a Statera Biopharma media release, the company has received Central Institutional Review Board (IRB) approval to conduct this trial, which is expected to begin in second quarter 2022.
- 29 Dec 2021 According to a Statera Biopharma media release, the trial sites are currently being selected and enrollment is expected to launch in early 2022.